5Vote!
PR News Wire (Free subscription) | yesterday
SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will...
4Vote!
Life Science World (Free subscription) | yesterday
[NEWS] Contact: SINC info@plataformasinc.es 34-914-251-820 FECYT - Spanish Foundation for Science and Technology Surplus biomass from the production of flax shives, and generated from Brassica carinata, a yellow-flowered plant related to those which engulf fields in spring, can be used to produce bioethanol. This has been sugg…
4Vote!
Life Science World (Free subscription) | yesterday
[NEWS] Contact: Dr. Henri Boffin hboffin@eso.org 49-893-200-6222 ESO Centaurus A (NGC 5128) is the nearest giant, elliptical galaxy, at a distance of about 11 million light-years. One of the most studied objects in the southern sky, by 1847 the unique appearance of this galaxy had already caught the attention of the famous British astronomer John Herschel, …
4Vote!
Life Science World (Free subscription) | yesterday
[NEWS] Contact: Joris Gansemans joris.gansemans@vib.be 32-472-594-067 VIB (the Flanders Institute for Biotechnology) Brussel, November 19th 2009 - Bacteria possess an ingenious mechanism for preventing oxygen from harming the building blocks of the cell. This is the new finding of a team of biologists that includes Joris Messens of VIB, a life science…
4Vote!
Life Science World (Free subscription) | yesterday
[NEWS] Contact: Ineke Boneschansker i.boneschansker@tudelft.nl 31-152-788-499 Delft University of Technology With the introduction of a single bacterial gene into yeast, researchers from Delft University of Technology in the Netherlands achieved three improvements in bioethanol production from agricultural waste material: 'More eth…
3Vote!
Medical News Today (Free subscription) | yesterday
Genzyme Corporation (Nasdaq: GENZ) reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme's Renvela® (sevelamer carbonate). Based on these results, the...
5Vote!
PR News Wire (Free subscription) | 11/19/2009
BLAUVELT, N.Y., Nov. 19 /PRNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.
5Vote!
PR News Wire (Free subscription) | 11/19/2009
COPENHAGEN, Nov. 19 /PRNewswire/ -- Danish Prince Joachim inaugurated the DONG Energy and Inbicon cellulosic ethanol plant in Kalundborg, Denmark, on Wednesday, November 18. The facility is one of the world's first and largest 2nd generation ethanol demonstration biorefineries. Genencor's Accellerase enzymes are used in the plant's innovative process for converting straw to fuel. Genencor, a Division...
5Vote!
PR News Wire (Free subscription) | 11/19/2009
ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the second consecutive year. The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective strategic use of acquisitions and divestitures since January 2006.
5Vote!
PR News Wire (Free subscription) | 11/19/2009
BEDFORD, Mass., Nov. 19 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE), a global provider of imaging and biometrics software, today announced it will showcase its new AccuRad ImageShare Platform, a standards-based cross-enterprise image sharing platform for health information exchange (HIE), at the RSNA 2009 Scientific Assembly and Annual Meeting. Aware will also participate in the Integrating...
5Vote!
PR News Wire (Free subscription) | 11/19/2009
MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
5Vote!
PR News Wire (Free subscription) | 11/19/2009
MUNSTER, Germany, November 19 /PRNewswire/ -- MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a...
5Vote!
PR News Wire (Free subscription) | 11/19/2009
BURLINGTON, Mass. and BERLIN, Nov. 19 /PRNewswire/ -- caprotec bioanalytics GmbH announced today the opening of its US-based subsidiary based in Burlington, MA. caprotec Inc. will be responsible for North American sales, marketing and support of caprotec's proprietary Capture Compound Mass Spectrometry (CCMS) technology and its related products.
5Vote!
Life Science World (Free subscription) | 11/19/2009
[NEWS] Contact: Dawn Peters physicalsciencenews@wiley.com 781-388-8408 Wiley-Blackwell Homo floresiensis not diseased sub-population of healthy humans Researchers from Stony Brook University Medical Center in New York have confirmed that Homo floresiensis is a genuine ancient human species an…
5Vote!
Life Science World (Free subscription) | 11/19/2009
[NEWS] Contact: Dawn Peters physicalsciencenews@wiley.com 781-388-8408 Wiley-Blackwell Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects Researchers from the German Sport University Cologne in Germany found that non-steroidal and tissue-selective anab…
5Vote!
aarkstore | 09/14/2009
Genentech, Inc. - Financial and Strategic Analysis Review Summary : Genentech, Inc. (Genentech) is a biotechnology company focused on research and development, manufacturing, and marketing of biotherapeutics. Genentech is developing the drugs across the unmet medical needs in cancer, asthma and angiogenic disorders. Major focus of Genentech is on three areas namely; oncology, immunology, and tissue...
4Vote!
aarkstore | 09/12/2009
MedImmune, Inc. - Strategic Analysis Review Summary MedImmune, LLC.( MedImmune), a biotechnology company focused on the development, manufacture and commercialization of medicines for the indications in Infectious Diseases, Oncology, Inflammatory Disease, cardiovascular, gastrointestinal disease and neuroscience. Its marketed products include Synagis, Ethyol, FluMist and other products. It is headquartered...
Videos